Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDRH Examining CryoLife Heart Valve Risks Following Tissue Recall

This article was originally published in The Gray Sheet

Executive Summary

CDRH is reviewing potential risks associated with CryoValve heart valves in the wake of an Aug. 14 recall order for CryoLife human tissue products
Advertisement

Related Content

CryoLife, FDA Extend Interim Operating Agreement To March 20
CryoLife, FDA Extend Interim Operating Agreement To March 20
Cryolife Preparing For FDA Reinspection, Files Corrective Action Plan
Cryolife Preparing For FDA Reinspection, Files Corrective Action Plan
Osteotech Tissue Recall Traced To Equipment Malfunction In Electrical Storm
Osteotech Tissue Recall Traced To Equipment Malfunction In Electrical Storm
Rhakoss Spinal Implant May Be Safer Alternative To Allograft – Orthovita
CryoLife SEC Probe Compounds Firm’s Regulatory Woes; FDA Issues Notice
CryoLife
CryoLife Reviewing Tissue Sterilization Process In Wake Of Warning Letter
Advertisement
UsernamePublicRestriction

Register

MT017015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel